argenx
Platform for antibody lead choice that supports the discovery of human antibody therapeutics.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 10.1x EV/Revenue -13.6x EV/EBITDA | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | $1.1b | Post IPO Equity |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 909 % | (17 %) | 199 % | 79 % | 72 % | 30 % | 21 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (60 %) | (169 %) | (18 %) | 6 % | 25 % | 33 % | 37 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (82 %) | (173 %) | (24 %) | 38 % | 25 % | 31 % | 36 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 117 % | 162 % | 70 % | 45 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
argenx is a biotechnology company focused on developing innovative immunology solutions to treat severe autoimmune diseases and cancer. The company operates in the biopharmaceutical market, collaborating with academic institutions and industry partners to translate scientific discoveries into therapeutic antibodies. One of its key products, cusatuzumab, is being developed in partnership with Janssen R&D to target hematological malignancies such as leukemia. The business model revolves around research and development, followed by licensing agreements and collaborations for commercialization. Revenue is generated through milestone payments, royalties, and product sales.
Keywords: biotechnology, immunology, autoimmune diseases, cancer, therapeutic antibodies, hematological malignancies, collaboration, licensing, research and development, commercialization.
